Riskpilot← Back to searchSign inGet full accessLUNGESPESIALISTENE DA
DAActiveOrg 991658890Blombakkane 2, 5354 StraumeMedical specialists activities · NACE 8622Est. 20076 employees
Revenue 2024
NOK 4,8M
-8% vs 2023
EBITDA margin
-1.4%
-134% vs 2023
Equity ratio
11.7%
Financial strength
Net profit 2024
NOK -230K
-855% vs 2023
| Revenue | NOK 4,8M | -8% |
| EBITDA | NOK -67K | -134% |
| Net profit | NOK -230K | -855% |
| Total assets | NOK 635K | -36% |
| Equity | NOK 74K | -76% |
| Employees | 6 | — |
Legal name
LUNGESPESIALISTENE DA
Org number
991658890
Legal form
Ansvarlig Selskap Med Delt Ansvar
NACE code
8622 · Medical specialists activities
Founded
22. september 2007
Share capital
—
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Legepraksis med spesialitet innen lungesykdommer. Selskapet skal også kunne delta i annen næringsvirksomhet, samt kunne foreta investeringer i aksjer og andre verdipapirer.
Address
Blombakkane 2, 5354 Straume
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 370 | 5 020 | 4 930 | 5 200 | 4 800 |
| Staff expenses | −2 432 | −2 888 | −2 878 | −2 895 | −2 746 |
| EBITDA | −117 | 253 | 302 | 198 | −67 |
| Depreciation & amort. | −7 | −39 | −129 | −164 | −161 |
| EBIT | −124 | 214 | 173 | 35 | −229 |
| Net financials | −0 | −0 | 0 | −4 | −1 |
| Profit before tax | −124 | 214 | 173 | 30 | −230 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −124 | 214 | 173 | 30 | −230 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 284 | 1 049 | 788 | 994 | 635 |
| Equity | −113 | 101 | 274 | 304 | 74 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 397 | 948 | 514 | 690 | 561 |
| Total debt | 397 | 948 | 514 | 690 | 561 |
EBITDA margin
-1.4%
This company
15.8%
Market median
-109% vs market
20202024
Equity ratio
11.7%
This company
38.2%
Market median
-69% vs market
20202024
Return on equity
-310.2%
This company
18.4%
Market median
-1786% vs market
20202024
Net profit margin
-4.8%
This company
8.1%
Market median
-159% vs market
20202024
Asset turnover
7.56×
This company
1.12×
Market median
+575% vs market
20202024
Debt / equity
7.57×
This company
0.62×
Market median
-1121% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
KS Chief Executive Officer | Chief Executive Officer | 2021 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Chairman | 2025 | |
| Chairman | 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 0% | 0% | 2019 | |
| Company | 0% | 0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LUNGESPESIALISTENE DA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Stang Volden | Chief Executive Officer | 0 companies |
| Jon Andrew Hardie | Deputy Chairman | 0 companies |
| Gunnar Reksten Husebø | Chairman | 0 companies |